Stephane Bancel - 09 Nov 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
09 Nov 2022
Net transactions value
-$14,817,062
Form type
4
Filing time
14 Nov 2022, 15:48:05 UTC
Previous filing
04 Nov 2022
Next filing
18 Nov 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $39,600 +40,000 +0.74% $0.9900* 5,451,946 09 Nov 2022 Direct F1
transaction MRNA Common Stock Sale $743,797 -4,552 -0.08% $163.40 5,447,394 09 Nov 2022 Direct F1, F2
transaction MRNA Common Stock Sale $1,312,055 -7,994 -0.15% $164.13 5,439,400 09 Nov 2022 Direct F1, F3
transaction MRNA Common Stock Sale $825,049 -4,987 -0.09% $165.44 5,434,413 09 Nov 2022 Direct F1, F4
transaction MRNA Common Stock Sale $2,370,321 -14,255 -0.26% $166.28 5,420,158 09 Nov 2022 Direct F1, F5
transaction MRNA Common Stock Sale $855,595 -5,112 -0.09% $167.37 5,415,046 09 Nov 2022 Direct F1, F6
transaction MRNA Common Stock Sale $370,260 -2,200 -0.04% $168.30 5,412,846 09 Nov 2022 Direct F1, F7
transaction MRNA Common Stock Sale $152,235 -900 -0.02% $169.15 5,411,946 09 Nov 2022 Direct F1, F8
transaction MRNA Common Stock Options Exercise $39,600 +40,000 +0.74% $0.9900* 5,451,946 10 Nov 2022 Direct F1
transaction MRNA Common Stock Sale $32,450 -200 -0% $162.25 5,451,746 10 Nov 2022 Direct F1, F9
transaction MRNA Common Stock Sale $2,099,456 -12,800 -0.23% $164.02 5,438,946 10 Nov 2022 Direct F1, F10
transaction MRNA Common Stock Sale $2,082,528 -12,600 -0.23% $165.28 5,426,346 10 Nov 2022 Direct F1, F11
transaction MRNA Common Stock Sale $1,133,560 -6,800 -0.13% $166.70 5,419,546 10 Nov 2022 Direct F1, F12
transaction MRNA Common Stock Sale $1,024,278 -6,114 -0.11% $167.53 5,413,432 10 Nov 2022 Direct F1, F13
transaction MRNA Common Stock Sale $250,376 -1,486 -0.03% $168.49 5,411,946 10 Nov 2022 Direct F1, F14
transaction MRNA Common Stock Sale $1,644,300 -10,000 -0.15% $164.43 6,634,880 10 Nov 2022 See Footnote F15, F16
holding MRNA Common Stock 9,050,372 09 Nov 2022 See Footnote F17

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -40,000 -1.5% $0.000000 2,627,155 09 Nov 2022 Common Stock 40,000 $0.9900 Direct F1, F18
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -40,000 -1.5% $0.000000 2,587,155 10 Nov 2022 Common Stock 40,000 $0.9900 Direct F1, F18
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.74 to $163.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.75 to $164.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.83 to $165.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.85 to $166.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $166.86 to $167.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $167.87 to $168.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F8 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $168.89 to $169.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F9 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.89 to $162.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F10 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.73 to $164.33. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F11 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.80 to $165.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F12 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.89 to $166.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F13 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $166.95 to $167.63. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F14 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $168.08 to $168.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F15 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019.
F16 These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F17 These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F18 This option is fully vested and exercisable.